Although some results in animal models and HD patients are controversial–depending on the model tested, type of pharmacological treatment, and period of drug administration–pharmacological modulation of A2AR, through agonist and antagonist drugs, has shown a neuroprotective effect by attenuating the behavioral symptoms and improving neurochemical parameters during HD progression. The gene discussed is ADORA2A; the disease is Huntington disease.